Yervoy
Shire and BMS secure NICE recommendations for oncology drugs
July 27, 2016Research and Development, Sales and Marketing BMS, Baxalta, NICE, Oncaspar, Shire, Yervoy, opdivo
The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Shire’s Oncaspar (pegaspargase) and Bristol-Myers Squibb’s …
BMS names Fouad Namouni as new oncology development head
July 26, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, Erbitux, Fouad Namouni, Taxol, Yervoy, appointment, opdivo
Bristol-Myers Squibb has announced the appointment of Fouad Namouni to the position of oncology development head, effective July 25, 2016. …
AbbVie and BMS partner for Rova-T, Opdivo, Yervoy cancer combo
July 26, 2016Manufacturing and Production, Research and Development AbbVie, BMS, Yervoy, opdivo, rova-t
AbbVie and Bristol-Myers Squibb have announced that they will collaborate on a clinical trial to test some of their leading …
FDA approves new uses for BMS’ Opdivo/Yervoy cancer combo
January 25, 2016Sales and Marketing BMS, Bristol-Myers Squibb, Yervoy, ipilimumabm melanoma, nivolumab, opdivo, skin cancer
The FDA has granted Bristol Myers Squibb an expanded indication for its two-cancer drug regimen Opdivo and Yervoy, to treat …
FDA approves Bristol-Myers Squibb’s skin cancer drug
October 29, 2015Sales and Marketing BMS, Bristol-Myers Squibb, Yervoy, ipilumumab, melanoma
The FDA has recommended Bristol-Myers Squibb’s cancer drug Yervoy (ipilimumab) for the adjuvant treatment of patients with melanoma. The drug, …
BMS immunotherapy combination impresses at ASCO
June 1, 2015Research and Development, Sales and Marketing ASCO, BMS, Yervoy, opdivo
Bristol-Myers Squibb has presented data showing that a combination of its immunotherapies Opdivo and Yervoy significantly increases survival in advanced …
EMA approves BMS’ Opdivo for advanced skin cancer
April 27, 2015Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Merck, Yervoy, ipilimumab, keytruda, melanoma, nivolumab, opdivo, pembrolizumab, skin cancer
Bristol-Myers Squibb has earned a recommendation from the EMA for its cancer immunotherapy treatment Opdivo as a monotherapy for patients …
Merck’s Keytruda trial stopped early after beating BMS’ Yervoy on survival
March 25, 2015Research and Development, Sales and Marketing BMS, Merck, Yervoy, ipilimumab, keytruda, pembrolizumab
A trial comparing two potential blockbuster cancer treatments has been stopped early, after Merck’s Keytruda beat BMS’ Yervoy in a …
BMS names operating officer as new chief executive
January 21, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Giovanni Caforio, Lamberto Andreotti, Yervoy, opdivo
Bristol-Myers Squibb’s chief operating officer Giovanni Caforio will be stepping in to Lamberto Andreotti’s shoes as chief executive from May …
GSK melanoma drug sees quick NICE nod
September 18, 2014Sales and Marketing Cancer, GSK, NICE, Tafinlar, Yervoy, dabrafenib, melanoma, skin cancer
NICE is recommending GlaxoSmithKline’s new melanoma treatment Tafinlar (dabrafenib) after the firm offered a discount for its medicine. In final …
BMS sues Merck over new melanoma drug
September 8, 2014Research and Development, Sales and Marketing BMS, FDA, Merck, PD-1 inhibitors, Yervoy, keytruda
Things are getting ugly between Bristol-Myers Squibb and Merck as the former company began legal proceedings against the latter over …
Bristol-Myers Squibb: following the string of pearls
September 8, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, BMS, GSK, Johanna Mercier, Pfizer, UCB, Yervoy, acquisitions
Bristol-Myers Squibb (BMS) is something of an enigma in the pharma industry. Whilst many of its big pharma peers are …
NICE and market access: time for reform?
August 26, 2014Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Bristol-Myers Squibb, NICE, Yervoy, reform
Earlier in the year, at the ABPI’s annual conference, the UK pharma lobby group released a new report suggesting that …
Storm brewing over Roche cancer drug price
August 8, 2014Medical Communications, Research and Development, Sales and Marketing Cancer, Haslam, Kadcyla, NICE, Roche, Yervoy, rejection
The Breakthrough Breast Cancer charity and England’s drug pricing watchdog NICE have both attacked Roche for not lowering the price …
NICE ‘yes’ for cancer drugs
July 23, 2014Sales and Marketing Astellas, BMS, Cancer, NICE, Xtandi, Yervoy
Two big-name oncology brands, Bristol-Myers Squibb’s Yervoy and Astellas Pharma’s Xtandi, have been given the nod by drug costs watchdog …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
